ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 2021

The Dual Benefits of Sodium-Glucose Cotransporter-2 Inhibitors for Recurrent Nephrolithiasis and Gout Flares Among Gout Patients with Type 2 Diabetes: New User, Active Comparator Target Trial Emulation Studies
Abstract Number: 2022

Could Initiation of Sodium Glucose Co-Transporter-2 Inhibitors Reduce the Need for Conventional Urate-Lowering Therapy and Flare Medications in Patients with Gout?Population-Based Target Trial Emulation Studies
Abstract Number: 2023

A PEGylated Mammalian Uricase Suitable for Intramuscular Administration to Patients with Refractory Chronic Gout
Abstract Number: 2024

Serum Urate Change Among Patients with Gout Treated with Anti-Hypertensive Medications: A Comparative Effectiveness Analysis
Abstract Number: 2025

Autonomic Nervous System Dysfunction Common Among Patients with Long COVID:Diagnosis and Treatment Implications
Abstract Number: 2026

Cardiovascular Risk Measured by PREVENT Calculator and Disease Activity in Patients with Systemic Lupus Erythematosus
Abstract Number: 2027

Clinical Features and Treatment of Retroperitoneal Fibrosis in a Referral Hospital and Literature Review
Abstract Number: 2028

Therapeutic Insights in VEXAS Syndrome from a Multicenter Study in Spain: Moving Towards Amore Specific and Effective Treatment
Abstract Number: 2029

Iron Deficiency in Familial Mediterranean Fever: A Study on 211 Adult Patients from the JIR Cohort
Abstract Number: 2030

The Development of the EULAR Score for the Definition of Disease Activity in Adult-onset Still’s Disease; The “DAVID” Project
Abstract Number: 2031

A Contemporary Assessment of the Burden of Malignancy in IgG4-Related Disease
Abstract Number: 2032

A Systematic Review of Treatment Strategies in VEXAS Syndrome
Abstract Number: 2033

Scleritis and the Rheumatologist. Does the Type of Scleritis Help to Distinguish an Infectious Cause from an Immune Cause? Among the Immune Causes, Does It Help Differentiate Between Systemic Causes and Those Limited to the Eye?
Abstract Number: 2034

Effectiveness and Tolerability of Tocilizumab in Systemic Autoimmune Rheumatic Disease Associated Intertistial Lung Disease
Abstract Number: 2035

Older Age and Higher Erythrocyte Sedimentation Rate Are Associated with Increased Disease Burden at Diagnosis in a Cohort of IgG4-Related Disease Patients

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].